Chapter 50: Anemias – Iron & Erythropoietin Therapy

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to The Deep Dive.

Today we're tackling a topic that looks pretty straightforward anemia, but wow, the pharmacology is really complex and absolutely critical for advanced practice.

It really is.

Our mission today isn't just defining low hemoglobin.

We want to take the therapeutic strategies from chapter 50 of pharmacotherapeutics for advanced practice and make them really practical, high stakes clinical knowledge for you.

That's exactly right, because for advanced practitioners,

the real challenge with anemia isn't just spotting that low HgB number.

It's knowing that pretty much every single type of anemia demands a totally different pharmacologic approach and stakes are high.

I mean, treating the wrong thing like say mistaking B12 for folate deficiency that can cause real irreversible harm.

So we've got to get past just the basic diagnosis and really focus squarely on the therapeutic strategy.

Okay, okay.

So let's start by maybe framing the problem.

Every lab's got its own range, but the World Health Organization gives us some pretty clear functional benchmarks, right?

Yeah, they do.

Functionally, we're generally talking about a hemoglobin level below 13 .0 g per deciliter for men and below 12 .0 for non -pregnant women.

Got it.

So those numbers are kind of the trigger.

Exactly.

They immediately kick off the classification process and we use this sort of dual system.

First, pathophysiology.

Is the body

failing to produce enough red cells or is it destroying them too quickly?

Production versus destruction.

Simple enough.

Right.

And second, morphology.

That's all about the cell size using the mean corpuscular volume or MCV.

Ah, the MCV.

I always forget how useful that one is.

Remind us why that's so key right at the start.

Well, it's incredibly helpful because like you said, it helps narrow down what could be dozens of potential causes to just maybe two or three possibilities almost instantly.

Okay.

The average adult MCV is usually around 80 to 96 femtoliters.

So if it's small, microcytic, you immediately think like iron deficiency anemia, maybe calicemia.

Makes sense.

And if it's large macrocytic, your brain should jump straight to B12 or folate deficiency.

That's a huge shortcut diagnostically.

It really is.

But here's something absolutely fundamental, a core clinical rule that governs everything we prescribe.

Okay.

Your evaluation always starts with checking patient stability, getting a really good history.

You know, is this new or has it been lifelong?

And doing a thorough physical exam.

Looking for clues like postural hypotension, swollen lymph nodes, even just hidden blood in the stool.

Exactly.

All those things.

Yeah.

But the bedrock principle, the one you cannot forget is this.

You initiate treatment only when you have a specific diagnosis, period.

You don't just start giving iron because the hemoglobin is low.

You have to prove is iron deficiency first.

Right.

Diagnose first, treat second.

Critical point.

Okay.

So we've covered the definition, the classification.

Let's tackle failure through destruction first.

A real crisis waiting to happen.

Sickle cell disease.

Yes.

SCD.

An autosomal recessive disorder creates incredible suffering and we see it predominantly in African and Hispanic Americans.

So what's the underlying pathology there?

What makes the pharmacology so necessary?

Well, it boils down to a tiny genetic change.

It swaps out normal hemoglobin A for this problematic hemoglobin S.

Okay.

Now, when that red blood cell loses oxygen, maybe because of stress, dehydration, high altitude, fever, whatever this hemoglobin S starts to polymerize, it forms these long, stiff, rod -like structures inside the cell.

And that's what bends the cell.

That's exactly what bends the erythrocyte into that characteristic sickle shape.

And those rigid misshapen cells, they get stuck.

They cause vaso occlusion, damage the microvasculature, and lead to those absolutely agonizing, painful crises that are the hallmark of the disease.

Horrible.

So prevention becomes absolutely key, which brings us to a really foundational drug for prophylaxis.

Hydroxyuria.

How does that actually work?

What's the mechanism that stops that sickling?

Hydroxyuria is interesting.

It kind of works on three main fronts.

First, it significantly ramps up the production of fetal hemoglobin.

But Hbf doesn't sickle, right?

Yeah, correct.

Hbf doesn't sickle, so having more of it is protective.

Second, it actually increases the water content inside the red blood cells, which sort of helps prevent them from clumping up.

Okay.

And third, consequently, it improves the overall deformability of those cells, even the ones that might be starting to and less need for chronic blood transfusions.

It's a cornerstone therapy.

Okay.

So for the advanced practitioner managing this, hydroxyuria is for prophylaxis, usually if someone's having, say, more than three crises a year.

That's the general guideline.

Yeah.

More than three crises per year.

And the dosing.

Adult starting dose is 15 milligram capsule, often rounded up to the nearest 500 milligram capsule.

Correct.

But the monitoring.

Yeah.

The monitoring is really intensive.

You have to check a CBC with differential and reticulocytes every four weeks.

Every four weeks?

Why so frequent?

What are we watching out for so closely in an outpatient setting?

Because hydroxyuria is mildly oppressive.

It can knock down the bone marrow's production of blood cells.

Our goal is to keep the absolute neutrophil count, the ANC at or above 2 ,000 per microliter, and the platelets at or above 80 ,000.

If those numbers drop below that, if you see

thrombocytopenia,

you absolutely have to hold the dose immediately.

So it's a constant balancing act.

It is.

You're balancing preventing crises against avoiding potentially serious toxicity.

And another thing to remember and to tell your patients is that it takes time.

A clinical response can take a frustrating three to six months to really show up.

Three to six months.

Okay.

And beyond the myelosuppression, what other side effects are we concerned about?

Remember things like skin changes.

Yeah.

You can see cutaneous

hyperpigmentation.

Leg ulcers can be a problem.

And there's also a long -term, though,

low risk of secondary cancers.

Right.

Okay.

Now stepping into newer agents, we have Voxelotor, brand name Oxbrida.

This one seems to take a more direct approach.

It does.

Voxelotor is approved for patients age 12 and older.

It's classified as an HBS polymerization inhibitor.

So it stops the rods from forming in the first place.

Exactly.

It literally binds to the hemoglobinous molecule and stabilizes it in its oxygenated state, preventing it from linking up and forming those stiff rods.

The standard dose is 1 ,500 milligrams taken orally once a day.

Okay.

Any big red flags for prescribers there?

Interactions?

Absolutely.

The big one is its metabolism via CYP3A4.

Voxelotor is a substrate.

So if your patient is taking a strong inhibitor of CYP3A4, you need to decrease the Voxelotor dose to a thousand milligram daily.

Got it.

Decrease inducers of CYP3A4.

You actually need to increase the Voxelotor dose up to 2 ,500 milligrams daily.

You really have to check those medication lists carefully.

Good pearl.

Okay.

And just briefly, for managing an acute sickle cell crisis itself, what's the approach?

It's about rapid assessment, first and foremost.

Then aggressive hydration, usually IV fluids, and really effective multimodal pain relief.

That often starts with things like acetaminophen or NSAIDs, but frequently requires IV opioids for severe pain.

And we should probably mention the caution against using Mapparadine, right?

Demerol.

Oh, definitely.

Mapparadine is generally avoided as a first -line opioid, especially for repeated use because its metabolite, Normaparadine, can accumulate and actually lower the seizure threshold.

Not something you want in an already stressed patient.

Good point.

Okay.

So that covers failure through destruction with SCD.

But honestly, the much more common problem is production, isn't it?

By far.

Let's start with the absolute king of nutritional deficiencies worldwide.

Iron deficiency anemia, or IDEA.

What are the main ways this happens?

How does production get halted?

Yeah.

IDEA is incredibly common.

The causes generally fall into three big buckets.

First, just not getting enough iron in the diet.

Think very restrictive vegetarian diets, for example.

Okay.

Insufficient intake.

Second, inadequate absorption.

This is a big one.

We see it in malabsorption syndromes like celiac disease, or maybe after certain surgeries like gastric bypass with the duodenum, which is the primary site for iron absorption, gets bypassed.

Makes sense.

And critically,

certain drugs and even foods can really mess with absorption.

Things like proton pump inhibitors, PPIs, these two antagonists, they reduce stomach acid needed to absorb iron.

Even coffee, tea, and milk can bind iron and reduce uptake.

Wow.

Even coffee and tea.

Good to know.

And the third bucket?

Increased demands.

The body just needs more iron than it's getting.

Classic examples are pregnancy, heavy menstruation in women, or during big growth spurts in adolescents.

And underlying all this, we always have to consider blood loss, right?

Even slow, hidden blood loss from the GI tract.

Absolutely.

In adults, especially men and post -menopausal women,

unexplained IDEA should always make you think about chronic, often occult, gastrointestinal

until proven otherwise.

Okay.

So given all these possibilities, how do we use lab tests to definitively nail down that it is iron deficiency and set our treatment path?

The classic lab pattern you're looking for is low serum iron and especially low ferritin.

Ferritin reflects the body's iron stores.

Alongside that, you'll typically see a high total iron binding capacity, or TIBC.

High TIBC because the body's transport proteins are empty and looking for iron.

Exactly.

The capacity is high because the available iron is low.

Here's your really high -yield diagnostic pearl, that ferritin concentration is the earliest and most sensitive indicator of iron depletion.

A level less than, say, 12 to 30 nanograms per liter, depending on the lab,

strongly suggests depleted stores.

And a TIBC over 400 micrograms per deciliter really points towards IDEA because the body's screaming for iron.

Ferritin first, then TIBC.

Got it.

Okay.

Diagnosis confirmed.

We move to oral iron replacement is usually the first step.

Yes, absolutely.

It's a preferred first line.

It's inexpensive.

It's generally very effective.

The typical adult starting dose aims for about 100 to 200 milligrams of elemental iron per day.

Elemental iron.

That's key because different salts have different amounts.

Precisely.

A common way to get this is with 325 milligram tablets of ferrous sulfate, usually taken two or three times a day.

Now, absorption is best on an empty stomach, maybe with some vitamin C or orange juice to help.

Ah, but there's the rub.

Taking iron on an empty stomach often causes pretty significant GI side effects, right?

Nausea, constipation, stomach cramps.

Exactly.

And that leads to a major practical challenge.

Compliance.

Patients feel awful.

They stop taking the iron.

So how do we handle that?

We know taking it without food maximizes absorption, but taking it with food helps with the side effects, even though it might cut absorption by, what, up to two thirds?

Yeah, it can reduce absorption by up to 66%.

It's a real balancing act and requires patient education.

You start by encouraging them to try it on an empty stomach.

If they absolutely cannot tolerate it, and many can't, then you have them take it with food.

You accept the lower absorption because some iron absorbed is better than none because they stop taking it altogether.

You just might need to treat them for longer.

Right.

A pragmatic approach.

When does that struggle with tolerance or maybe a serious absorption issue push us towards using IV iron instead?

IV iron is really reserved for specific situations.

Things like documented chronic bleeding where oral iron just can't keep up, confirmed malabsorption syndromes, documented intolerance or failure of an adequate trial of oral iron, or in really severe cases, say a hemoglobin down below 6 GDL with signs of poor perfusion like dizziness or chest pain.

Hmm.

Okay.

Reserved for specific needs.

And once we start treatment, how do we track success?

What are the goals and how long does it take?

You should see the reticular site count.

Those are young red blood cells start to spike up within about 7 to 10 days.

That shows the bone marrow is responding.

Good early sign.

Yeah.

And the hemoglobin itself should start to increase by about 0 .7 to 1 gram per deciliter per week.

But it's not a quick fix for the underlying problem.

Right.

We need to refill the stores.

Exactly.

Therapy usually needs to continue for a good three to six months after the hemoglobin normalizes.

You're aiming to fully replete the body's iron stores.

And we often track this by aiming for a serum ferritin level of maybe around 50 nanograms per liter, though some sorts of say higher.

Three to six months after normalization.

Important reminder.

And don't forget drug interactions.

Oh, absolutely.

Oral iron can chelate, meaning bind up certain antibiotics like tetracyclines and fluoroquinolones, reducing the absorption of both drugs.

And as we mentioned, antacids, PPIs, H2 blockers, they all reduce iron absorption by decreasing stomach acid.

Timing is key.

Okay.

Let's shift gears slightly to another type of production failure.

The anemia of chronic renal failure or CRF.

This isn't a nutrient deficiency.

It's more of a hormone problem.

Precisely.

The primary issue here is that the disease kidneys just aren't producing enough erythropoietin or EPO, which is the hormone that tells the bone marrow to make red blood cells.

So production slows down because the signal isn't getting through.

Exactly.

And the therapeutic goals here are guided by some pretty strict guidelines like KDIGO and the FDA.

The aim is to reach a target hemoglobin concentration somewhere between 10 and 12 grams per deciliter.

10 to 12.

Not necessarily normal.

No, definitely not pushing for fully normal levels.

And critically, you want to use the lowest possible dose of what we call erythropoiesis stimulating agents or ESAs to achieve that target and importantly, prevent the need for blood transfusions.

The absolute key instruction is you must reduce the dose or even therapy if the hemoglobin level goes above 11 GDL.

Okay, do not exceed 11.

Why is that upper limit so critical?

We'll come back to that.

Let's look at the ESAs themselves first.

We have echoetin alpha like epogen or procrit and the longer acting darbapoietin alpha.

How do they compare?

They both work the same way.

They're recombinant versions of human erythropoietin.

They step in for the failing kidneys and stimulate red blood cell production and differentiation in the bone marrow.

So they provide the missing signal.

Exactly.

The main practical difference is their duration of action, their half -life.

Epogen has a shorter half -life, around 8 .5 hours, so it typically needs dosing maybe three times a week.

Darbapoietin was engineered to last longer.

Its half -life is about 25 hours, so it allows for less frequent dosing, often just once weekly or even less often in some cases.

Okay, convenience factor with darbapoietin.

Is there anything we need to check before starting an ESA?

Absolutely crucial point.

You must ensure the patient has adequate iron before you start ESA therapy.

Makes sense.

You can send the signal, but if there are no building blocks.

Exactly.

You can't build red blood cells without iron.

So you check their iron status ferritin TSAT and or to pleat iron if necessary before or concurrently with starting the ESA.

Otherwise, the ESA just won't work effectively.

Right.

Build the foundation first.

Now back to that monitoring and the strict upper limit.

Dosing examples are like apuetin 50 to 100 unit scary subcutaneously three times weekly if hgb is under 10 or darbapoietin 0 .45 mil cgkogiv or se once weekly.

But the adjustments are key.

You mentioned monitoring hgb weekly at first.

Yes, especially when initiating therapy or making dose adjustments.

Weasley monitoring is often recommended.

And the rule is if the hemoglobin rises too fast, say more than one gdl in a two -week period, you have to cut the dose back maybe by 25 percent or more.

Why such strictness?

What's the danger of pushing that hgb too high above 11?

This is critically important.

That strict target range of 10 to 11 or maybe up to 12 and some guidelines isn't just about efficacy.

It's primarily about safety.

Safety.

Studies have clearly shown that targeting higher hemoglobin levels, say above 11 or 12 gdl with the essays doesn't provide additional benefit and in fact significantly increases the patient's risk of serious cardiovascular events.

Like what?

We're talking increased risk of stroke, heart attack, heart failure, blood clots, including thrombosis of vascular access in dialysis patients.

There's even concern about increased risk of tumor progression in some cancer patients, although that's a slightly different context.

Wow, so driving the hgb too high is actively harmful.

Actively harmful.

That's why using the lowest effective dose is paramount and why uncontrolled hypertension is an absolute contraindication for starting es8 but you have to get the blood pressure under control first.

Uncontrolled hypertension,

contraindication.

Got it.

Okay, that covers CRF.

Let's quickly tackle our final therapeutic challenge.

The two main macrocytic anemias, B12 deficiency and folate deficiency.

These often get confused, right?

They do.

They both cause large red blood cells, macrocytosis, and can share symptoms like fatigue, weakness, shortness of breath.

But the distinction is absolutely crucial.

Potentially the difference between full recovery and permanent disability.

Okay, let's start with vitamin B12 cyanocobalamin.

What causes this deficiency?

Well, a common cause is a lack of intrinsic factor.

That's a protein made in the stomach that's necessary to absorb B12 in the terminal ilium.

Without it, you get pernicious anemia.

This can happen autoimmunely or after surgeries like gastrectomy that remove the part of the stomach, making intrinsic factor.

Okay, lack of intrinsic factor or just decreased absorption.

Right.

Other causes involve decreased absorption further down the line, maybe due to diseases affecting the ilium like Crohn's disease or even long -term use of medications like metformin or PPIs can interfere with absorption.

The clinical danger, the thing every practitioner must remember, is that severe prolonged B12 deficiency can cause irreversible neurologic damage.

Irreversible, that's the key word.

What kind of neurologic problems?

It can manifest in various ways.

Paranoia, confusion,

memory loss, depression,

but classically peripheral neuropathy, particularly affecting the posterior and lateral columns of the spinal cord, leading to loss of position sense, loss of vibratory sensation, and an unsteady gait.

Okay, so spotting this early is vital.

How do we diagnose it definitively?

Serum B12 level.

Serum B12 level is the first step, yes, but it's not always perfectly reliable, especially in borderline cases.

It tells you what's circulating, but not necessarily what's happening inside the cells or tissues.

Right, so that's where those other markers come in, methylmalonic acid, MMA, and homocysteine.

Why are they often better indicators?

Exactly.

B12 is needed for specific metabolic reactions.

When B12 is deficient at the cellular level, the substrates for those reactions, specifically MMA and homocysteine, build up in the blood.

Ah, they accumulate because the pathway is blocked.

Precisely.

So if you see both an elevated homocysteine level and, critically, an elevated MMA level, that strongly confirms a functional B12 deficiency, even if the serum B12 level itself is borderline low or low normal.

Elevated homocysteine A and D, elevated MMA, equals B12 deficiency.

Got it.

And treatment.

Traditionally, it was injections, right?

Yes, the traditional approach, especially for pernicious anemia where oral absorption is impaired, is parenchial B12, usually starting with something like a thousand micrograms intramuscularly daily for a week, then weekly for a month, then monthly for life.

Monthly injections for life.

That can be tough for compliance.

It can be.

Which is why it's good to know that high dose oral B12, typically 1 ,000 to 2 ,000 micrograms daily, has actually shown comparable efficacy in many cases, even in pernicious anemia, likely through mass action absorption pathways.

So oral therapy is often a viable and sometimes preferred alternative now.

Good to know.

Okay, now quickly, folate deficiency.

Folate is also crucial, right, for DNA synthesis.

Absolutely.

Folate is essential for nucleic acid synthesis, for making DNA and RNA.

So deficiency also leads to problems with rapidly dividing cells like blood cells.

And the causes, similar to B12 in some ways.

Somewhat.

Inadequate dietary intake is a big one, often seen in people with poor diets, chronic alcoholism.

Malabsorption syndromes can play a role.

And also increased requirements pregnancy is the classic example, which is why prenatal vitamins are loaded with folic acid.

Certain drugs, like methotrexate or some anti -seizure meds, can also interfere with folate metabolism.

Okay.

Symptoms can overlap with B12 fatigue, weakness.

But what's the crucial difference again?

The absolute key distinction.

Folate deficiency does not cause the neurologic manifestations seen in B12 deficiency.

You get the macrocytic anemia, the fatigue, the sore tongue maybe, but you don't get the neuropathy, the confusion, the spinal cord issues.

No neuro symptoms.

That's the divider.

And how do we confirm it with labs differentiating it from B12?

Here's where those metabolic markers are critical again.

In folate deficiency you'll see an elevated homocysteine level, because folate is also needed for its metabolism.

But the MMA level will be normal.

Elevated homocysteine, normal MMA, folate deficiency.

Exactly.

That normal MMA is the key differentiator from B12 deficiency.

Treatment is usually straightforward.

Oral folic acid, typically one milligram daily, is usually sufficient to correct the deficiency and replete stores.

Okay.

One milligram folic acid daily seems simpler than B12.

It generally is once you've correctly identified it and ruled out concurrent B12 deficiency, which is important, because giving folate alone to someone who is actually B12 deficient can mask the anemia hematologically, while allowing the potentially devastating neurologic to progress silently.

Ah, another critical point.

Never treat suspected folate deficiency without checking B12 status first.

Always.

Rule out B12 first.

Okay.

That covers the main therapeutic landscapes.

Let's try to pull together the most essential takeaways for our advanced nursing student listeners.

What's the overarching theme?

I think the absolute key therapeutic strategy is precision.

The specific type of anemia diagnosis must drive the treatment choice.

We've seen it across the board, whether you're choosing hydroxyurea to target the specific cellulopathy of sickle cell disease, or using simple iron salts for a straightforward nutritional deficiency like ID,

or employing ESAs to replace a missing hormone signal in chronic kidney disease.

That precise diagnosis is absolutely paramount for selecting the right drug and avoiding harm.

Precision is key.

And any final high -yield clinical pearls for practice?

Definitely.

Remember those key values.

Ferritin is your earliest clue for ID.

And that MMA homocysteine combination is indispensable for accurately distinguishing between B12 and folate deficiency.

Get that wrong, and the consequences can be severe.

MMA and homocysteine.

Burn that into memory.

And never forget the safety implications we discussed with ESAs in chronic kidney disease.

That danger of targeting hemoglobin too high above 11 GDL is real.

Increased risk of stroke, clots, heart failure.

And remember that uncontrolled hypertension is a definite contraindication.

Monitoring those parameters isn't just about checking boxes.

It's actively protecting your patient from serious harm.

Excellent recap.

Monitoring matters.

And maybe I'll leave you with one final thought to mull over.

We focus a lot on starting therapies, but managing anemia is often like playing chess, thinking several moves ahead.

Oh, so?

Well, think about conditions

transfusions, like severe thalassemia major.

While transfusions rapidly fix the anemia, that chronic iron loading leads inevitably to hemocytosis iron overload.

Ah, fixing one problem creates another.

Exactly.

And that iron overload then requires its own complex, long -term, and often difficult pharmacologic treatment with iron chelation therapy, using drugs like deferroximin or newer oral agents.

It just highlights how every choice we make in managing anemia can have really significant downstream consequences.

You always have to anticipate the next potential pharmacologic challenge.

That's a powerful perspective.

Fixing the HDB isn't always the end of the story.

Thank you so much for walking us through this complex landscape today.

My pleasure.

It's crucial information.

Absolutely.

Thanks everyone for joining us for this deep dive into anemia pharmacology.

We'll catch you next time.